176 related articles for article (PubMed ID: 21453270)
21. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
22. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.
Muroi Y; Saito T; Takahashi M; Sakuyama K; Niinuma Y; Ito M; Tsukada C; Ohta K; Endo Y; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2014; 29(5):360-6. PubMed ID: 24647041
[TBL] [Abstract][Full Text] [Related]
23. Effect of 22 Novel Cytochrome P450 2D6 (CYP2D6) Variants Found in the Chinese Population on Hemangeol Metabolism In Vitro.
Liang B; Zhan Y; Huang X; Gu E; Dai D; Cai J; Hu G
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):759-765. PubMed ID: 26542054
[TBL] [Abstract][Full Text] [Related]
24. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
25. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
Kudo S; Odomi M
Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
[TBL] [Abstract][Full Text] [Related]
26. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese.
Wang SL; Lai MD; Huang JD
Drug Metab Dispos; 1999 Mar; 27(3):385-8. PubMed ID: 10064570
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450: genetic polymorphism and drug interactions.
Belpaire FM; Bogaert MG
Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
[TBL] [Abstract][Full Text] [Related]
28. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
29. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
30. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
31. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
[TBL] [Abstract][Full Text] [Related]
32. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.
Zhou SF; Liu JP; Lai XS
Curr Med Chem; 2009; 16(21):2661-805. PubMed ID: 19601803
[TBL] [Abstract][Full Text] [Related]
33. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
[TBL] [Abstract][Full Text] [Related]
34. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.
Yoshii K; Kobayashi K; Tsumuji M; Tani M; Shimada N; Chiba K
Life Sci; 2000; 67(2):175-84. PubMed ID: 10901285
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
Ramamoorthy Y; Tyndale RF; Sellers EM
Pharmacogenetics; 2001 Aug; 11(6):477-87. PubMed ID: 11505218
[TBL] [Abstract][Full Text] [Related]
36. Nanocomposites of graphene and cytochrome P450 2D6 isozyme for electrochemical-driven tramadol metabolism.
Cui D; Mi L; Xu X; Lu J; Qian J; Liu S
Langmuir; 2014 Oct; 30(39):11833-40. PubMed ID: 25222611
[TBL] [Abstract][Full Text] [Related]
37. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
38. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
39. Heterotropic cooperativity in oxidation mediated by cytochrome p450.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2008 Jun; 9(5):453-62. PubMed ID: 18537580
[TBL] [Abstract][Full Text] [Related]
40. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.
Venhorst J; Onderwater RC; Meerman JH; Commandeur JN; Vermeulen NP
Drug Metab Dispos; 2000 Dec; 28(12):1524-32. PubMed ID: 11095593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
